Bio-Techne FY2026 10-K: Flat Sales, 148% GAAP EPS Jump, and a $1B Wilson Wolf Obligation
TECH sits 67% above its 52-week low of $43.195 on light trading volume (0.3× avg).
Summary
Bio-Techne's FY2026 10-K reports flat revenue of $1.215B, GAAP EPS of $1.16 (up 148% YoY), and a $1B+ forward obligation to acquire the rest of Wilson Wolf by end of 2027.
Key Events · Earnings and Guidance · TECH
-
FY2026 Revenue Flat at $1.215B
Consolidated net sales were $1.215B, flat versus fiscal 2025. Organic revenue was flat, with a 2% favorable FX impact offset by a 2% unfavorable impact from a held-for-sale business.
-
GAAP Net Earnings Up 148% to $181.9M
GAAP net earnings rose 148% to $181.9M ($1.16 diluted EPS), driven by a non-recurring prior-year impairment charge and arbitration award. Adjusted net earnings declined 1% to $303.3M ($1.93 adjusted diluted EPS) on unfavorable product mix and pricing.
-
$1B+ Wilson Wolf Acquisition Obligation
The company must acquire the remaining 80.1% of Wilson Wolf by December 31, 2027 for approximately $1B plus potential contingent consideration, with acceleration possible if Wilson Wolf reaches $226M annual revenue or $136M annual EBITDA.
-
Merger Termination Fees Disclosed
The 10-K discloses a $230.5M termination fee payable by Bio-Techne and a $576.1M termination fee payable by Merck KGaA under specified circumstances related to the pending $73/share all-cash acquisition.
Analysis · TECH · Life Sciences
Bio-Techne's fiscal 2026 annual report shows flat revenue at $1.215B but a 148% surge in GAAP net earnings to $181.9M, driven by a prior-year impairment charge and arbitration award that did not recur. Adjusted net earnings actually declined 1% to $303.3M on unfavorable product mix and pricing pressure. The filing also reveals a significant future cash obligation: the company must acquire the remaining 80.1% of Wilson Wolf by December 31, 2027 for approximately $1B plus potential contingent consideration, which could be accelerated if Wilson Wolf hits certain revenue or EBITDA milestones. This is a material capital commitment that investors need to understand, especially given the pending $73/share all-cash acquisition by Merck KGaA.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 29.3% of the 1512 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TECH was trading at $72.33 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.3B. The 52-week trading range was $43.20 to $72.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.